Financiële Diensten Amsterdam

Financiële Diensten Amsterdam (“FDA”) delivers ‘buy-side’ equity research and active portfolio construction for professional clients. Our focus is directed at European and US Large-Cap companies with a ‘free float’ market capitalization exceeding EUR 10 billion.

Based in Amsterdam, a team of 25 dedicated analysts with a wide variety of backgrounds is responsible for the rigorous selection and portfolio-construction. We have been providing these services for over 30 years, based on independent, in-house research. We target well managed western companies with a sustainable and defendable competitive edge. They benefit from globalization and structural growth opportunities.

Our concentrated portfolios are managed in an unconstrained way and based on ‘high conviction’ ideas. The main objective is an attractive and consistent (out) performance for our clients. Our thoroughness and long term perspective are central to this objective.

The Large-Cap mandates from institutional clients are managed in an advice-only manner, in the sense that we are not involved in the execution of the transactions. Our clients can choose their own custodian and broker.

Our flagship portfolio, consisting of 65 stocks, is the FDA Blue Chips Equity portfolio, launched in June 2003, and has delivered an average annual performance of +11%. In total, on the FDA research platform, there are more than 125 companies analyses, including in-depth ESG analyses.

To view an example of our research, a summary sustainability report is downloadable from the FDA listing on the Euro IRP Directory.